The Vivos OSA device. Image courtesy of Vivos Therapeutics.
Vivos Therapeutics announced that orders for its obstructive sleep apnea (OSA) treatment devices increased 26% following 510(k) approval by the U.S. Food Drug and Administration (FDA) in November 2023.
During the fourth quarter of 2023, Vivos reported that new dentist inquiries increased 600% over the previous month and signed dentist enrollment contracts were up 38% sequentially compared to the third quarter following the clearance of its CARE oral medical devices.
